Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Kursexplosion von 383 % seit November und massiver Solana-Outperformer!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E2FN | ISIN: NO0013107490 | Ticker-Symbol: I8X0
Frankfurt
22.01.25
08:09 Uhr
0,007 Euro
0,000
0,00 %
Branche
IT-Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
IDEX BIOMETRICS ASA Chart 1 Jahr
5-Tage-Chart
IDEX BIOMETRICS ASA 5-Tage-Chart
GlobeNewswire (Europe)
261 Leser
Artikel bewerten:
(1)

IDEX BIOMETRICS ASA: IDEX Biometrics interim report for the third quarter of 2024

Finanznachrichten News

Oslo, Norway - 29 October 2024 - IDEX Biometrics ASA's interim report for the third quarter is attached to this notice (link below). The interim report is also available on the IDEX Biometrics website: www.idexbiometrics.com/investors/interim-results/

A webcast presentation of the interim report will be held by Catharina Eklof, Chief Executive Officer, today at 09:00 CET. The webcast presentation is attached to this notice (link below), and can be viewed at the following link:

https://idexbiometrics.videosync.fi/q3-2024

"Transitioning into the CEO role this quarter, my focus has been on executing our transformation program and implementing key initiatives to achieve the targeted cash quarterly operating expense run rate of $2.5 million. By the end of the third quarter, IDEX had executed on targeted reorganization initiatives, significantly reducing operating expenses. We have consolidated our technology and administrative teams into the UK and Europe, and optimized our entire workforce to capture the fast growing opportunity across the APAC region." Said Catharina Eklof, Chief Executive Officer at IDEX Biometrics.

Ms. Eklof added, "On the customer side, we continue to expand our manufacturing partners and solution integrators with our open software platforms and flexible operating system. Focus over the last quarters has been on supporting manufacturers from certification to industrialized production. As a result, KONA I has achieved Mastercard approval for the world first metal biometric card, based on the IDEX Pay platform. A first commercial program is now in the planning phase of being rolled out in Asia."

In September, IDEX demonstrated a successful live transaction on the India based RuPay network with IDEX Pay, together with our manufacturing partners. This is a leading indicator of the IDEX biometric platform readiness to bring trusted identity solutions to consumers around the world.

Financials:

  • Revenues in the third quarter totaled $0.1M.
  • Net Income in Q3 was $1.4M with Adjusted Net Loss of $4.8M. Adjustments are related to the restructuring charges and the derivative value changes.
  • Operating expenses reduced to $4.1M, a reduction of $2.0M from last quarter.
  • Restructuring cost during Q3 were $0.4M including severance and other items. Restructuring gain of $0.7M resulting from two lease cancellations.
  • On track to achieve a cash operating run-rate of $2.5M per quarter by the end of this year.
  • Recorded a gain of $5.5M from a change in the derivative value related to outstanding warrants and the favorable renegotiation of our outstanding convertible bond.

For further information contact:
Marianne Bøe, Head of Investor Relations
E-mail: ir@idexbiometrics.com
Tel: + 47 67 83 91 19

About IDEX Biometrics
IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As an industry-enabler we partner with leading card manufacturers and technology companies to bring our solutions to market.

For more information, visit www.idexbiometrics.com

TRADEMARK STATEMENT
IDEX, TrustedBio, IDEX Biometrics and the IDEX logo are trademarks owned by IDEX Biometrics ASA. All other brands or product names are the property of their respective holders.


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.